tiprankstipranks
Trending News
More News >

Verastem price target raised to $14 from $10 at H.C. Wainwright

H.C. Wainwright analyst Sean Lee raised the firm’s price target on Verastem (VSTM) to $14 from $10 and keeps a Buy rating on the shares after the company’s avutometinib plus defactinib combination received accelerated approval from the FDA for the treatment of low-grade serous ovarian cancer.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue